Your browser doesn't support javascript.
loading
Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor.
Jiang, Longying; Liu, Xueke; Wei, Hudie; Dai, Shuyan; Qu, Lingzhi; Chen, Xiaojuan; Guo, Ming; Chen, Yongheng.
Afiliación
  • Jiang L; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Liu X; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Wei H; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Dai S; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Qu L; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Chen X; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Guo M; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • Chen Y; Department of Pathology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. Electronic address: yonghenc@163.com
Biochem Biophys Res Commun ; 595: 1-6, 2022 03 05.
Article en En | MEDLINE | ID: mdl-35091108
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azetidinas / Receptores Citoplasmáticos y Nucleares / Simulación del Acoplamiento Molecular / Dominios Proteicos / Ácidos Isonicotínicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azetidinas / Receptores Citoplasmáticos y Nucleares / Simulación del Acoplamiento Molecular / Dominios Proteicos / Ácidos Isonicotínicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos